Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CNR2 | P34972 | 6/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837668 | 0.88 | CNR2 (0.71) | TAS2R14MEN1KMT2ACNR2ALDH1A1 | |
| SCHEMBL3483545 | 0.88 | TAS2R14 (0.58) | TAS2R14MEN1KMT2ACNR2PTPN1 | |
| SCHEMBL6121673 | 0.87 | KMT2A (0.58) | TAS2R14MEN1KMT2ACNR2PTPN1 | |
| SCHEMBL4413527 | 0.87 | HTR2A (0.75) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL3817627 | 0.87 | TAS2R14 (0.61) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL4243334 | 0.87 | BACE1 (0.71) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL8911635 | 0.87 | TAS2R14 (0.78) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL5295487 | 0.85 | TAS2R14 (0.64) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL4924397 | 0.85 | TAS2R14 (0.64) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL4917430 | 0.85 | CNR2 (0.68) | TAS2R14MEN1KMT2ACNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117832615-A | Functional additive, electrolyte and lithium-sulfur battery | 江西微电新能源有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | claimed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | claimed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-0446982-B1 | Low-temperature bleaching compositions | UNILEVER NV (NL) | 1994-10-26 | — | — | EP | claimed |
| EP-0446982-A2 | Low-temperature bleaching compositions | UNILEVER N.V. (NL) | 1991-09-18 | — | — | EP | claimed |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117832615-A | Functional additive, electrolyte and lithium-sulfur battery | 江西微电新能源有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | disclosed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-7868194-B2 | Process for the preparation of 21-hydroxy steroids with control of the epimeric distribution at the C-21 position | INDUSTRIALE CHIMICA S.R.L. (IT) | 2011-01-11 | — | — | US | disclosed |
| EP-1809649-B1 | PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION | IND CHIMICA SRL (IT) | 2010-03-17 | — | — | EP | disclosed |
| US-20080114180-A1 | Process for the Preparation of 21-Hydroxy Steroids with Control of the Epimeric Distribution at the C-21 Position | INDUSTRIALE CHIMICA S.R.L. (IT) | 2008-05-15 | — | — | US | disclosed |
| EP-1809649-A1 | PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION | INDUSTRIALE CHIMICA S.r.l. (IT) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006045745-A1 | PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION | INDUSTRIALE CHIMICA S.R.L. (IT) | 2006-05-04 | — | — | WO | disclosed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | TAS2R14 3597/4885MEN1 2065/4885KMT2A 2131/4885 |
| US-20080114180-A1 | Process for the Preparation of 21-Hydroxy Steroids with Control of the Epimeric Distribution at the C-21 Position | CYP17A1, CYP21A2, HSD17B7 | TAS2R14 4575/4885MEN1 303/4885KMT2A 2463/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | TAS2R14 1594/4885MEN1 1041/4885KMT2A 2861/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | TAS2R14 1478/4885MEN1 3676/4885KMT2A 4144/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | TAS2R14 3225/4885MEN1 2026/4885KMT2A 1594/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | TAS2R14 4287/4885MEN1 3184/4885KMT2A 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.